Harvard Bioscience analyst ratings
Harvard Bioscience analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/05/2022 | 94.44% | Keybanc | $10 → $7 | Maintains | Overweight |
| 11/10/2020 | 66.67% | Keybanc | → $6 | Initiates Coverage On | → Overweight |
| 02/27/2020 | 11.11% | Benchmark | $3.5 → $4 | Maintains | Speculative Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/05/2022 | 94.44% | KeyBanc | $10 → $7 | 維護 | 超重 |
| 11/10/2020 | 66.67% | KeyBanc | → $6 | 開始承保 | →超重 |
| 02/27/2020 | 11.11% | 基準 | $3.5 → $4 | 維護 | 投機性購買 |
Harvard Bioscience Questions & Answers
哈佛生物科學問答
The latest price target for Harvard Bioscience (NASDAQ: HBIO) was reported by Keybanc on August 5, 2022. The analyst firm set a price target for $7.00 expecting HBIO to rise to within 12 months (a possible 94.44% upside). 1 analyst firms have reported ratings in the last year.
Keybanc於2022年8月5日報道了哈佛生物科學公司(納斯達克代碼：HBIO)的最新目標價。這家分析公司將目標價定為7.00美元，預計HBIO將在12個月內上漲至94.44%。1家分析公司在過去一年公佈了評級。
The latest analyst rating for Harvard Bioscience (NASDAQ: HBIO) was provided by Keybanc, and Harvard Bioscience maintained their overweight rating.
最新分析師對哈佛生物科學公司(納斯達克代碼：HBIO)的評級是由Keybanc提供的，哈佛生物科學公司維持其增持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harvard Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harvard Bioscience was filed on August 5, 2022 so you should expect the next rating to be made available sometime around August 5, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公開的財務報表，與哈佛生物科學的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。哈佛生物科學的上一次評級是在2022年8月5日提交的，所以你應該預計下一次評級將在2023年8月5日左右的某個時候公佈。
While ratings are subjective and will change, the latest Harvard Bioscience (HBIO) rating was a maintained with a price target of $10.00 to $7.00. The current price Harvard Bioscience (HBIO) is trading at is $3.60, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的哈佛生物科學(HBIO)評級維持不變，目標價在10.00美元至7.00美元之間。哈佛生物科學公司(HBIO)目前的交易價格為3.60美元，超出了分析師的預測範圍。